Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects

NCT05979727 is registered in ClinicalTrials.gov with Reconnect Labs as lead sponsor.

NCT NCT05979727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05979727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
Lead sponsor
Reconnect Labs
Phase
Phase 1
Overall status
Terminated
Start date
November 20, 2023
Completion date
December 10, 2023
Enrollment
4 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy